Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
1.300
+0.022 (1.70%)
Mar 9, 2026, 1:21 PM EDT - Market open
Lyra Therapeutics Employees
Lyra Therapeutics had 30 employees as of December 31, 2024. The number of employees decreased by 58 or -65.91% compared to the previous year.
Employees
30
Change (1Y)
-58
Growth (1Y)
-65.91%
Revenue / Employee
$20,000
Profits / Employee
-$1,098,233
Market Cap
2.31M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| Calidi Biotherapeutics | 28 |
| Ensysce Biosciences | 8 |
| Artelo Biosciences | 7 |
| CDT Equity | 6 |
| Adial Pharmaceuticals | 5 |
| PMGC Holdings | 3 |
| 60 Degrees Pharmaceuticals | 3 |
LYRA News
- 2 months ago - Lyra Therapeutics Provides Corporate Update - GlobeNewsWire
- 4 months ago - Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study - GlobeNewsWire
- 7 months ago - Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 9 months ago - Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha
- 10 months ago - Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga
- 10 months ago - Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewsWire